MYRIAD GENETICS INC
Myriad Genetics (MYGN) is a US-based molecular diagnostics company focused on hereditary cancer screening, oncology companion diagnostics and predictive tests that inform treatment decisions. It generates revenue from diagnostic testing services, licensing intellectual property and partnerships with biopharma for companion diagnostics. With a market capitalisation of about $749.94M, it sits in the small-cap segment and can show above-average volatility compared with larger peers. Investors should understand the company’s sensitivity to reimbursement policies, regulatory decisions and competitive pressure from other diagnostics firms. Clinical validation, new test launches or favourable payer coverage can act as catalysts, while declines in test volumes or adverse rulings can weigh on results. This summary is for educational purposes only and not personalised investment advice; suitability depends on individual circumstances and investors should consider risk tolerance, diversification and seek professional advice if needed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Myriad Genetics stock, with a target price of $7.70, indicating potential growth.
Financial Health
Myriad Genetics is performing well with strong revenue, solid profit margins, and healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
AXOGEN INC
AxoGen provides products for the peripheral nerve reconstruction and regeneration.
ADAPTHEALTH CORP
Provides home medical products direct to consumers and to healthcare providers.
Baskets Featuring MYGN
The Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Genetic Testing Focus
Specialises in hereditary cancer and oncology tests; rising demand for personalised medicine could support growth, though reimbursement and competition create uncertainty.
Growth & Catalysts
New test approvals, partnerships and improved payer coverage can boost revenue, but volumes and pricing remain variable and may cause swings in results.
Market & Risks
Market cap under $1bn implies small‑cap risks such as lower liquidity and earnings unpredictability; regulatory and reimbursement outcomes are key drivers.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
